Skip to content
Dr Rangan ChatterjeeDr Rangan Chatterjee

Doctors Won't Tell You This! - Dark Truth About Antidepressants & How Big Pharma Fooled Everyone

CAUTION: If you are taking antidepressants or any other psychiatric medication, do not stop or adjust your dosage without first consulting a qualified healthcare professional. Coming off these medications without proper guidance can lead to serious withdrawal symptoms. Always seek professional advice before making changes to your treatment. This episode is brought to you by: BON CHARGE: Save 20% off with code LIVEMORE https://boncharge.com/livemore WHOOP: Try the New WHOOP today at https://join.whoop.com/livemore AG1: Get 1 year's Free Vitamin D3+K2 and 5 free travel packs https://bit.ly/43FwxQl VIVOBAREFOOT: Get 20% off your first order https://bit.ly/4l2txWU Did you know that nearly one in five UK adults - and almost one in four women - are currently taking antidepressants? Yet according to my guest this week, the fundamental theory behind these prescriptions may be built on remarkably shaky ground. Joanna Moncrieff is Professor of Critical and Social Psychiatry at University College London, consultant psychiatrist for the NHS, and the author of the groundbreaking book, Chemically Imbalanced: The Making and Unmaking of the Serotonin Myth. In our thought-provoking conversation, Joanna explains how the widely accepted belief that depression is caused by a chemical imbalance or serotonin deficiency has little scientific evidence to support it. This theory, which became popularised in the 1990s through pharmaceutical industry marketing, has fundamentally changed how we view our emotions and mental health. Joanna and I discuss: • Why the difference between antidepressants and placebos in clinical trials is just two points on a 54-point depression scale - a remarkably small difference that may not be clinically significant • How the diagnosis of depression itself is subjective and based on criteria that Joanna describes as "completely made up", rather than objective biological markers • The concerning side effects of SSRIs that are often underreported - including emotional numbness, sexual dysfunction that can persist even after stopping medication, and in some cases, an increase in suicidal thoughts • How pharmaceutical marketing campaigns in the 1990s fundamentally changed our cultural understanding of depression from a natural human response to life circumstances to a "chemical imbalance" requiring medication • Why withdrawal from antidepressants can be extremely challenging, particularly at lower doses, and why reducing medication requires careful, gradual reduction that many doctors aren't trained to manage • Whether visiting your GP should be your first option when experiencing low mood, and how alternatives like exercise, mindfulness and addressing underlying life issues might be more effective Throughout the episode, Joanna encourages us to view our emotional responses as meaningful signals rather than medical disorders that need chemical correction. She believes we've been disempowering people by teaching them that negative emotions represent a deficiency rather than a natural human experience that can guide us toward necessary changes in our lives. This conversation isn't about telling anyone what to do with their current medication, but rather providing information to make truly informed decisions. If you or someone you know has ever taken antidepressants or been diagnosed with depression, this episode offers a perspective that could fundamentally change how you view mental health treatment in the future. I hope you enjoy listening. #feelbetterlivemore ----- Show notes https://drchatterjee.com/563 Connect with Professor Moncrieff: https://x.com/joannamoncrieff https://www.joannamoncrieff.com Professor Moncrieff’s latest book: Chemically Imbalanced: The Making and Unmaking of the Serotonin Myth US https://amzn.to/4kZow1d UK https://amzn.to/43CKC3R #feelbetterlivemore #feelbetterlivemorepodcast ------- Order MAKE CHANGE THAT LASTS. US & Canada version https://amzn.to/3RyO3SL, UK version https://amzn.to/3Kt5rUK ----- Follow Dr Chatterjee at: Website: https://drchatterjee.com/ Facebook: https://www.facebook.com/drchatterjee Twitter: https://twitter.com/drchatterjeeuk Instagram: https://www.instagram.com/drchatterjee/ Newsletter: https://drchatterjee.com/subscription DISCLAIMER: The content in the podcast and on this webpage is not intended to constitute or be a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have heard on the podcast or on my website.

Dr. Rangan ChatterjeehostJoanna Moncrieffguest
Jun 10, 20251h 49mWatch on YouTube ↗

At a glance

WHAT IT’S REALLY ABOUT

Challenging serotonin myth: antidepressant marketing, modest benefits, significant harms, withdrawal

  1. Moncrieff argues the serotonin/chemical-imbalance story became “fact” largely through 1990s pharmaceutical marketing rather than strong biological evidence.
  2. They claim SSRI trials show only a small average improvement over placebo (about 2 points on a 54-point depression scale), with significant concerns about unblinding and expectancy effects amplifying perceived benefit.
  3. The conversation emphasizes meaningful, commonly reported adverse effects—emotional blunting, sexual dysfunction (including reports of persistence after stopping), lethargy/agitation, and increased suicidal ideation in some groups.
  4. They contend depression diagnosis and rating scales are inherently subjective and culturally shaped, and that medicalizing distress can reduce agency, obscure real-life causes, and worsen long-term outcomes.
  5. Practical guidance is offered: don’t stop abruptly; taper slowly using updated resources (Royal College of Psychiatrists guidance, Maudsley Deprescribing Guidelines), and prioritize non-drug approaches such as exercise, mindfulness, and talking therapies.

IDEAS WORTH REMEMBERING

5 ideas

The serotonin-deficiency story is presented as marketing-driven, not evidence-settled.

Moncrieff says the theory existed earlier but gained mass acceptance in the 1990s when SSRI promotion repeatedly framed depression as a chemical imbalance, leading public and clinician beliefs to harden into “fact.”

Average SSRI benefits over placebo in trials are small and may not be clinically meaningful.

They cite an approximately 2-point difference on a 54-point depression scale and argue this often fails to translate into noticeable functional improvement on broader clinical ratings.

Trial “double blinding” may be compromised, inflating apparent drug effects.

Because side effects can reveal who received the active drug, expectations can boost outcomes; Moncrieff cites evidence that believing you’re on the drug can produce larger score changes than the drug–placebo average difference.

Depression diagnosis and measurement are subjective and context-dependent.

The episode highlights how criteria (e.g., “two weeks”) are conventional thresholds, and ratings can be influenced by language, cultural framing, and how emotionally expressive a person appears.

SSRIs are framed as mind-altering drugs with tradeoffs, not targeted “corrections.”

Without a proven underlying deficiency to correct, the risk-benefit calculation shifts toward viewing SSRIs as substances that alter normal brain states—sometimes producing emotional numbing, lethargy, agitation, and sexual side effects.

WORDS WORTH SAVING

5 quotes

And I think that is absolutely shocking. I think it matters a lot how they work, and it is absolutely essential that we discuss this with the public and, and so that people are able to evaluate what they might be doing to them if they're thinking about taking one of these drugs.

— Joanna Moncrieff

One of the common effects they have, for example, is that they cause a state of emotional numbing. So people often say that they can't, um, you know, they may not feel quite so sad anymore, but also they can't feel happy anymore, and they can't cry.

— Joanna Moncrieff

The difference between taking an antidepressant and taking a placebo in these placebo-controlled trials is two points on this o- on, on this common depression rating scale, which is a, which has a maximum score of 54 points. So it's a very small difference.

— Joanna Moncrieff

I think we need to de-medicalize depression radically.

— Joanna Moncrieff

That it's a mind... Exactly, that it's a mind-altering drug.

— Joanna Moncrieff

Origins and spread of the “chemical imbalance” narrativeSSRI evidence base and placebo/unblinding effectsSubjectivity of depression diagnosis and rating scalesAdverse effects: emotional blunting and sexual dysfunctionWithdrawal, dependence, and tapering complexity (hyperbolic dosing)Pharmaceutical marketing influence on clinicians and public beliefsDe-medicalizing distress and expanding non-drug supports

High quality AI-generated summary created from speaker-labeled transcript.

Get more out of YouTube videos.

High quality summaries for YouTube videos. Accurate transcripts to search & find moments. Powered by ChatGPT & Claude AI.

Add to Chrome